Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00878163

Title field or adapter rule

{'original_value': 'Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.416510+00:00

Published At

2026-09-08T00:00:00+00:00

Record Updated At

2026-09-08

Source Retrieved At

2026-10-31T22:17:58.991924+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Adult Solid Neoplasm", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer AJCC v6 and v7"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-08", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT00878163"

protocolSection.identificationModule.officialTitle

"Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Adult Solid Neoplasm (protocolSection.conditionsModule.conditions)
• Pancreatic Acinar Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Recurrent Pancreatic Carcinoma (protocolSection.conditionsModule.conditions)
• Stage IV Pancreatic Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)'], 'description': 'Correlative studies', 'name': 'Diagnostic Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)'], 'description': 'Given PO', 'name': 'Erlotinib Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)'], 'description': 'Given IV', 'name': 'Gemcitabine Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)'], 'description': 'Given PO', 'name': 'Vismodegib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Erlotinib Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)
• Vismodegib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.